Logo image of ACAD

ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD

21.74  -0.56 (-2.51%)

After market: 21.74 0 (0%)

Fundamental Rating

6

Taking everything into account, ACAD scores 6 out of 10 in our fundamental rating. ACAD was compared to 559 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ACAD suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
In the past 5 years ACAD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ACAD reported negative operating cash flow in multiple years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of 20.23%, ACAD belongs to the top of the industry, outperforming 97.50% of the companies in the same industry.
Looking at the Return On Equity, with a value of 29.93%, ACAD belongs to the top of the industry, outperforming 97.67% of the companies in the same industry.
ACAD has a Return On Invested Capital of 9.30%. This is amongst the best in the industry. ACAD outperforms 94.81% of its industry peers.
Industry RankSector Rank
ROA 20.23%
ROE 29.93%
ROIC 9.3%
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

ACAD's Profit Margin of 22.99% is amongst the best of the industry. ACAD outperforms 95.71% of its industry peers.
ACAD's Operating Margin of 8.84% is amongst the best of the industry. ACAD outperforms 93.74% of its industry peers.
The Gross Margin of ACAD (92.08%) is better than 93.20% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
Industry RankSector Rank
OM 8.84%
PM (TTM) 22.99%
GM 92.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

7

2. Health

2.1 Basic Checks

ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
Compared to 5 years ago, ACAD has more shares outstanding
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ACAD has an Altman-Z score of 5.14. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
ACAD's Altman-Z score of 5.14 is fine compared to the rest of the industry. ACAD outperforms 78.53% of its industry peers.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.14
ROIC/WACC0.97
WACC9.56%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ACAD has a Current Ratio of 2.87. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD's Current ratio of 2.87 is on the low side compared to the rest of the industry. ACAD is outperformed by 66.73% of its industry peers.
ACAD has a Quick Ratio of 2.80. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.80, ACAD is not doing good in the industry: 65.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.8
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 5000.00% over the past year.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 22.39%.
ACAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.08% yearly.
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%

3.2 Future

Based on estimates for the next years, ACAD will show a very strong growth in Earnings Per Share. The EPS will grow by 43.51% on average per year.
The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y23.76%
EPS Next 2Y35.18%
EPS Next 3Y42.64%
EPS Next 5Y43.51%
Revenue Next Year9.35%
Revenue Next 2Y10.02%
Revenue Next 3Y10.61%
Revenue Next 5Y10.46%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2 3

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 44.37 indicates a quite expensive valuation of ACAD.
Based on the Price/Earnings ratio, ACAD is valued cheaply inside the industry as 92.49% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.60, ACAD is valued quite expensively.
The Price/Forward Earnings ratio is 24.78, which indicates a rather expensive current valuation of ACAD.
ACAD's Price/Forward Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.23% of the companies in the same industry.
ACAD's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.39.
Industry RankSector Rank
PE 44.37
Fwd PE 24.78
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

ACAD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ACAD is cheaper than 92.31% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.77% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 73.53
EV/EBITDA 37.86
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 42.64% in the coming years.
PEG (NY)1.87
PEG (5Y)N/A
EPS Next 2Y35.18%
EPS Next 3Y42.64%

More info and screens

0

5. Dividend

5.1 Amount

ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (6/12/2025, 5:20:00 PM)

After market: 21.74 0 (0%)

21.74

-0.56 (-2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners99.79%
Inst Owner Change6.94%
Ins Owners0.29%
Ins Owner Change4.02%
Market Cap3.64B
Analysts76.15
Price Target27.26 (25.39%)
Short Float %9.2%
Short Ratio6.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.13%
Min EPS beat(2)-109.07%
Max EPS beat(2)-3.19%
EPS beat(4)2
Avg EPS beat(4)-15.12%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)7
Avg EPS beat(12)13.32%
EPS beat(16)10
Avg EPS beat(16)17.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)0.08%
Revenue beat(4)2
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.72%
Revenue beat(16)7
Avg Revenue beat(16)-1.86%
PT rev (1m)10.37%
PT rev (3m)8.03%
EPS NQ rev (1m)-16.27%
EPS NQ rev (3m)-25.9%
EPS NY rev (1m)-10.24%
EPS NY rev (3m)-19.95%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)1.06%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)1.4%
Valuation
Industry RankSector Rank
PE 44.37
Fwd PE 24.78
P/S 3.65
P/FCF 73.53
P/OCF 24.42
P/B 4.76
P/tB 5.61
EV/EBITDA 37.86
EPS(TTM)0.49
EY2.25%
EPS(NY)0.88
Fwd EY4.03%
FCF(TTM)0.3
FCFY1.36%
OCF(TTM)0.89
OCFY4.1%
SpS5.95
BVpS4.57
TBVpS3.87
PEG (NY)1.87
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.23%
ROE 29.93%
ROCE 10.62%
ROIC 9.3%
ROICexc 9.3%
ROICexgc 10.83%
OM 8.84%
PM (TTM) 22.99%
GM 92.08%
FCFM 4.97%
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 151.14%
Profit Quality 21.61%
Current Ratio 2.87
Quick Ratio 2.8
Altman-Z 5.14
F-Score5
WACC9.56%
ROIC/WACC0.97
Cap/Depr(3y)241.2%
Cap/Depr(5y)203.04%
Cap/Sales(3y)1.85%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y23.76%
EPS Next 2Y35.18%
EPS Next 3Y42.64%
EPS Next 5Y43.51%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
Revenue Next Year9.35%
Revenue Next 2Y10.02%
Revenue Next 3Y10.61%
Revenue Next 5Y10.46%
EBIT growth 1Y1912.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.12%
EBIT Next 3Y44.84%
EBIT Next 5Y49.94%
FCF growth 1Y188.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y367.79%
OCF growth 3YN/A
OCF growth 5YN/A